» Articles » PMID: 32979457

Exosomes Derived from Human Placenta-derived Mesenchymal Stem Cells Improve Neurologic Function by Promoting Angiogenesis After Spinal Cord Injury

Overview
Journal Neurosci Lett
Specialty Neurology
Date 2020 Sep 26
PMID 32979457
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Spinal cord injury (SCI) is a serious central nervous system condition with no effective clinal treatment. Recently, transplantation of bone marrow mesenchymal stem cells (MSCs) derived exosomes has been proposed as a potential treatment for SCI. However, whether exosomes have similar functions as transplanted human placenta-derived MSCs(hPMSCs) has remained unclear.

Methods: The hPMSCs-derived exosomes (hPMSCs-Exos) were extracted using a sequential centrifugation approach. Then, the effects of hPMSCs-Exos on angiogenesis were analysis both in vitro and in vivo. In addition, the sensory and locomotor functions of mice after SCI were also analyzed.

Results: The administration of hPMSCs-Exos promote the tube formation and migration of human umbilical vein endothelial cell (HUVECs). Furthermore, vessel numbers, vessel volume fraction and vessel connectivity in spinal cords significantly increased after exosomes were intrathecally injected in the SCI model. In addition, the locomotor and sensory function, also significantly improved in the exosome treatment group.

Conclusions: The results of the present study demonstrated that hPMSCs-Exos have proangiogenic effects on endothelial cells and enhanced angiogenesis in SCI model. Thus, this treatment strategy demonstrates great potential for the treatment of SCI.

Citing Articles

Angiogenesis-promoting effect of SKP-SC-EVs-derived miRNA-30a-5p in peripheral nerve regeneration by targeting LIF and ANGPT2.

Shen M, Ye X, Zhou Q, Zheng M, Du M, Wang L J Biol Chem. 2024; 301(2):108146.

PMID: 39732166 PMC: 11791313. DOI: 10.1016/j.jbc.2024.108146.


Advances in therapies using mesenchymal stem cells and their exosomes for treatment of peripheral nerve injury: state of the art and future perspectives.

Aldali F, Deng C, Nie M, Chen H Neural Regen Res. 2024; 20(11):3151-3171.

PMID: 39435603 PMC: 11881730. DOI: 10.4103/NRR.NRR-D-24-00235.


Exosomes as promising bioactive materials in the treatment of spinal cord injury.

Li Y, Luo W, Meng C, Shi K, Gu R, Cui S Stem Cell Res Ther. 2024; 15(1):335.

PMID: 39334506 PMC: 11438208. DOI: 10.1186/s13287-024-03952-5.


Stem Cell-Derived Exosomes as a Therapeutic Option for Spinal Cord Injuries; a Systematic Review and Meta-Analysis.

Jabermoradi S, Paridari P, Adel Ramawad H, Gharin P, Roshdi S, Toloui A Arch Acad Emerg Med. 2024; 13(1):e2.

PMID: 39318865 PMC: 11417640. DOI: 10.22037/aaem.v12i1.2261.


Intravenous administration exosomes derived from human amniotic mesenchymal stem cells improves neurological recovery after acute traumatic spinal cord injury in rats.

Zhou H, Wang J, Zhao P, Le D, Cai S, Mao G Iran J Basic Med Sci. 2024; 27(10):1284-1292.

PMID: 39229573 PMC: 11366944. DOI: 10.22038/ijbms.2024.76532.16576.